These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1281532)

  • 1. Striatal neuropeptide levels in Parkinson's disease patients.
    Fernandez A; de Ceballos ML; Jenner P; Marsden CD
    Neurosci Lett; 1992 Oct; 145(2):171-4. PubMed ID: 1281532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease.
    Fernandez A; de Ceballos ML; Rose S; Jenner P; Marsden CD
    Brain; 1996 Jun; 119 ( Pt 3)():823-30. PubMed ID: 8673494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parallel alterations in Met-enkephalin and substance P levels in medial globus pallidus in Parkinson's disease patients.
    de Ceballos ML; Fernandez A; Jenner P; Marsden CD
    Neurosci Lett; 1993 Oct; 160(2):163-6. PubMed ID: 7504224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Striatal expression of substance P and methionin-enkephalin in genes in patients with Parkinson's disease.
    Levy R; Vila M; Herrero MT; Faucheux B; Agid Y; Hirsch EC
    Neurosci Lett; 1995 Oct; 199(3):220-4. PubMed ID: 8577402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia.
    Taylor MD; De Ceballos ML; Rose S; Jenner P; Marsden CD
    Eur J Pharmacol; 1992 Aug; 219(2):183-92. PubMed ID: 1385171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain neuropeptides in progressive supranuclear palsy.
    Taquet H; Javoy-Agid F; Mauborgne A; Benoliel JJ; Agid Y; Legrand JC; Hamon M; Cesselin F
    Brain Res; 1987 May; 411(1):178-82. PubMed ID: 2440513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine dependent decrease in enkephalin and substance P levels in basal ganglia regions of postmortem parkinsonian brains.
    Sivam SP
    Neuropeptides; 1991 Apr; 18(4):201-7. PubMed ID: 1711165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropeptide levels in the basal ganglia of aged common marmosets following prolonged treatment with MPTP.
    Taylor MD; de Ceballos ML; Rose S; Chong PN; Jenner P; Marsden CD
    J Neural Transm Park Dis Dement Sect; 1991; 3(2):99-108. PubMed ID: 1716907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.
    Ciesielska A; Samaranch L; San Sebastian W; Dickson DW; Goldman S; Forsayeth J; Bankiewicz KS
    PLoS One; 2017; 12(2):e0169965. PubMed ID: 28166239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of Met-enkephalin, Leu-enkephalin, substance P and cholecystokinin in the brain of the common marmoset following long term 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine treatment.
    Taquet H; Nomoto M; Rose S; Jenner P; Javoy-Agid F; Mauborgne A; Benoliel JJ; Marsden CD; Legrand JC; Agid Y
    Neuropeptides; 1988 Oct; 12(3):105-10. PubMed ID: 2468106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topography of enkephalin, substance P and acetylcholinesterase staining in Huntington's disease striatum.
    Ferrante RJ; Kowall NW; Richardson EP; Bird ED; Martin JB
    Neurosci Lett; 1986 Nov; 71(3):283-8. PubMed ID: 2432445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substance P and cholecystokinin regulate neurochemical responses to cocaine and methamphetamine in the striatum.
    Loonam TM; Noailles PA; Yu J; Zhu JP; Angulo JA
    Life Sci; 2003 Jun; 73(6):727-39. PubMed ID: 12801594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subgroups of parkinsonian patients differentiated by peptidergic immunostaining of caudate nucleus biopsies.
    De Ceballos ML; López-Lozano JJ
    Peptides; 1999; 20(2):249-57. PubMed ID: 10422881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical study of the striatal efferents and nigral dopaminergic neurons in parkinsonism-dementia complex on Guam in comparison with those in Parkinson's and Alzheimer's diseases.
    Goto S; Hirano A; Matsumoto S
    Ann Neurol; 1990 May; 27(5):520-7. PubMed ID: 1694418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropeptide metabolism on intact, regional brain slices: effect of dopaminergic agents on substance P, cholecystokinin and Met-enkephalin degradation.
    Waters SM; Konkoy CS; Davis TP
    J Pharmacol Exp Ther; 1995 Aug; 274(2):783-9. PubMed ID: 7543572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical demonstration of differential substance P-, met-enkephalin-, and glutamic-acid-decarboxylase-containing cell body and axon distributions in the corpus striatum of the cat.
    Beckstead RM; Kersey KS
    J Comp Neurol; 1985 Feb; 232(4):481-98. PubMed ID: 2579980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain enkephalin receptors in Parkinson's disease.
    Rinne UK; Rinne JK; Rinne JO; Laakso K; Tenovuo O; Lönnberg P; Koskinen V
    J Neural Transm Suppl; 1983; 19():163-71. PubMed ID: 6321647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of lumbar CSF levels of met-enkephalin, encrypted met-enkephalin, and neuropeptide Y in normal patients and in patients with Parkinson's disease before and after autologous transplantation of adrenal medulla into the caudate nucleus.
    Yaksh TL; Carmichael SW; Stoddard SL; Tyce GM; Kelly PJ; Lucas D; van Heerden JA; Ahlskog JE; Byer DE
    J Lab Clin Med; 1990 Mar; 115(3):346-51. PubMed ID: 2313164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
    Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
    Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study.
    Nimura T; Yamaguchi K; Ando T; Shibuya S; Oikawa T; Nakagawa A; Shirane R; Itoh M; Tominaga T
    J Neurosurg; 2005 Dec; 103(6):968-73. PubMed ID: 16381182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.